CRTC2 and tuberous sclerosis: If the dual targeting of TORC1/TORC2 will be able to introduce a superior efficacy when compared to that of everolimus, without further significant toxicity, these newer agents might open new windows of opportunity to the treatment of several conditions, including TSC.